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Baccari MC, Nistri S, Vannucchi MG, Calamai F, Bani D.
Reversal by relaxin of altered ileal spontaneous contractions in dys-
trophic (mdx) mice through a nitric oxide-mediated mechanism. Am J
Physiol Regul Integr Comp Physiol 293: R662–R668, 2007. First
published May 23, 2007; doi:10.1152/ajpregu.00214.2007.—Altered
nitric oxide (NO) production/release is involved in gastrointestinal
motor disorders occurring in dystrophic (mdx) mice. Since the hor-
mone relaxin (RLX) can upregulate NO biosynthesis, its effects on
spontaneous motility and NO synthase (NOS) expression in the ileum
of dystrophic (mdx) mice were investigated. Mechanical responses of
ileal preparations were recorded in vitro via force-displacement trans-
ducers. Evaluation of the expression of NOS isoforms was performed
by immunohistochemistry and Western blot. Normal and mdx mice
were distributed into three groups: untreated, RLX pretreated, and
vehicle pretreated. Ileal preparations from the untreated animals
showed spontaneous muscular contractions whose amplitude was
significantly higher in mdx than in normal mice. Addition of RLX,
alone or together with L-arginine, to the bath medium depressed the
amplitude of the contractions in the mdx mice, thus reestablishing a
motility pattern typical of the normal mice. The NOS inhibitor
NG-nitro-L-arginine (L-NNA) or the guanylate cyclase inhibitor ODQ
reversed the effects of RLX. In RLX-pretreated mdx mice, the
amplitude of spontaneous motility was reduced, thus resembling that
of the normal mice, and NOS II expression in the muscle coat was
increased in respect to the vehicle-pretreated mdx animals. These
results indicate that RLX can reverse the altered ileal motility of mdx
mice to a normal pattern, likely by upregulating NOS II expression
and NO biosynthesis in the ileal smooth muscle.
L-arginine; nitric oxide synthase; muscular dystrophy; intestinal mo-
tility
DUCHENNE MUSCULAR DYSTROPHY (DMD) is an X-linked disease
which results in severe myopathy characterized by progressive
skeletal muscle degeneration. Lack or reduced expression of
the actin-binding protein dystrophin is the primary genetic
defect leading to DMD (46). Loss of dystrophin leads to
reduction of the dystrophin-associated protein complex, which
causes disruption of the anchorage between cortical cytoskel-
eton and extracellular matrix and eventually plasma membrane
rupture and necrosis of skeletal muscle fibers (31). Dystrophin
is also needed to bind nitric oxide synthase (NOS) to the inner
surface of the sarcolemma (12): in DMD patients as well as in
mdx mice, an animal model of DMD (13), the sarcolemma is
devoid of NOS (12, 15), suggesting that NOS defect and
consequent disruption of intrinsic nitric oxide (NO) pathway
may contribute to the pathophysiology of muscular dystrophy
and may be a possible target for therapeutic strategies (26). In
normal animals and humans, besides the skeletal muscle,
dystrophin is also present in cardiac and smooth muscle and in
some neurons. Accordingly, previous studies indicate that
DMD not only affects the skeletal muscle but also the cardiac
(19) and the smooth muscles (37). Visceral diseases, such as
gastric dilatation and hypomotility or intestinal constipation
and pseudoobstruction, are indeed present in DMD patients
(10, 27). In some cases, gastrointestinal dysfunction may even
precede the onset of typical musculoskeletal disorders (37).
Recent studies have revealed that motor disorders affect the
gastrointestinal tract of mdx mice and have provided evidence
that these dysfunctions are related, at least in part, to impaired
NO production/release (1, 7, 33). NO derives from L-arginine
by the catalytic action of three distinct NOS isoforms (35).
In the gut, NO released by the enteric nerves and/or produced
by the smooth muscle is considered the major inhibitory
substance that modulates cholinergic neurotransmission and
causes gastrointestinal relaxation (5, 14, 30, 39, 45, 52). Ac-
cordingly, NO overproduction or defect is involved in several
gastrointestinal motor disorders (48). Recently, decreased
overall NO production has been found in DMD patients (26),
and NO donors have been proposed as palliative treatment of
Duchenne and Becker muscular dystrophies (16). Therefore,
substances able to increase endogenous NO production could
be useful therapeutic tools to counteract gastrointestinal symp-
toms in dystrophic patients. In this view, several lines of
evidence indicate that the peptide hormone relaxin (RLX) may
upregulate NO production in cells and tissues of reproductive
and nonreproductive organs (4, 8, 20, 40, 42). Recently, we
have shown that RLX markedly affects gut motor responses by
increasing NOS expression in the normal mouse ileum (9) and
stomach (3, 6). The present study was designed to investigate
whether RLX could also influence the abnormal motility pat-
tern of ileal preparations from mdx mice, paying special
attention to its possible effects on endogenous NO synthesis
pathway.
MATERIALS AND METHODS
Experiments were carried out on male normal (C57BL/10SnJ) and
dystrophic (C57BL/10ScSn mdx) mice (Jackson Laboratory), 8–12
wk old, fed standard laboratory chow, and housed under a 12–12 h
light/dark photoperiod. The experimental protocol complied with the
Principles of Laboratory Animal Care (NIH publication 86-23, revised
1985) and recommendations of the European Economic Community
(86/609/CEE) and was approved by the local ethical committee.
Normal and mdx mice were distributed into three groups. The mice
of the first group (14 normal and 14 mdx animals) received no
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treatment and are referred to as “untreated” normal or mdx mice. The
animals were killed by cervical dislocation and the ileum was re-
moved for functional studies. Mice of the second group (5 normal and
5 mdx animals), referred to as “RLX-pretreated” normal or mdx mice,
received a single subcutaneous injection of 2 g of highly purified
porcine RLX (2,500–3,000 U/mg), prepared according to Sherwood
and O’Byrne (43), generously donated by Dr. O. D. Sherwood,
University of Illinois, Urbana, IL. The hormone was dissolved 0.2 ml
of 1% benzopurpurin (Fluka, Buchs, Switzerland) in PBS, an inert
repository vehicle that allows a slow release of the hormone over 24 h.
The chosen dose, vehicle, and route of administration were in the
range of those previously used in mice and proved effective to
upregulate NOS expression (3, 6, 9). The RLX plasma levels yielded
by this administration protocol were measured by ELISA using a
commercial kit (Immundiagnostik, Bensheim, Germany). The mice of
the third group (5 normal and 5 mdx animals) received the vehicle
alone and are referred to as “vehicle-pretreated” normal or mdx mice.
Eighteen hours after injection of RLX or vehicle, the pretreated
normal and mdx mice of both groups were killed by cervical dislo-
cation, and ileal tissue samples were taken for functional studies and
for evaluation of NOS expression. Further details are given in the
following sections.
Functional studies on ileal contractility. Upon euthanasia, distal
segments of the ileum, transversely cut into segments, were isolated
from untreated and pretreated normal and mdx animals. They were
placed in Krebs-Henseleit solution composed of (in mmol/l) 118
NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 2.5 CaCl2, and
10 glucose, pH 7.4, and bubbled with 95% O2/5% CO2. Temperature
was maintained within a range of 37  0.5°C. Isometric tension was
continuously recorded by a force-displacement transducer (model
FT03; Grass, Quincy, MA) coupled to a polygraph (model 7700;
Sanborn, Waltham, MA). The preparations were allowed to equili-
brate for at least 1 h under an initial load of 1.5 g. During this period,
the preparations underwent repeated and prolonged washes with
Krebs-Henseleit solution to avoid metabolite accumulation in the
organ baths.
A first series of data was obtained by evaluating the effects of the
addition of the following drugs to the bath medium: the muscarinic
receptor antagonist atropine sulfate (1 mol/l), the nerve blocker
tetrodotoxin (TTX, 1 mol/l), the NO donor sodium nitroprusside
(SNP, 30 mol/l).
A second series of data was obtained by evaluating the effects of
the addition of RLX to the bath medium (50 nmol/l), alone or in
combination with the following drugs: the natural NOS substrate
L-arginine (L-Arg, 1 mmol/l), the NOS inhibitor NG-nitro-L-arginine
(L-NNA, 1 mmol/l), and the guanylate cyclase inhibitor 1H-[1,2,4]
oxadiazolo[4,3-a]-quinoxalin-1-one (ODQ, 1 mol/l). The reported
concentrations were the final bath concentrations. All drugs except
RLX were obtained from Sigma (St. Louis, MO).
Evaluation of NOS expression by immunohistochemistry. After
euthanasia, ileal fragments from normal and mdx mice pretreated for
18 h with vehicle or RLX, contiguous to those used for functional
studies, were fixed by immersion in paraformaldehyde 4% in PBS, pH
7.4, for 4 h, cryoprotected by incubation in sucrose 30% in PBS
overnight, washed in PBS, and quickly frozen at 80°C in cryostat
embedding medium (Bio-Optica, Milan, Italy). Cryostat sections, 12
m thick, were cut from each fragment and immunostained overnight
at 4°C with rabbit polyclonal antibodies to reveal the different NOS
isoforms: the constitutive, endothelial-type NOS (eNOS or NOS III,
1:200; Calbiochem, San Diego, CA), the inducible NOS (iNOS or
NOS II, 1:400; Calbiochem), or the constitutive, neuronal-type NOS
(nNOS or NOS I, 1:500; Chemicon, Temecula, CA). Immune reaction
was revealed by FITC-labeled goat anti-rabbit antibodies (working
dilution of 1:200, Jackson Immunoresearch) at room temperature for
2 h and viewed and photographed under a fluorescence microscope
with a 40 objective.
Evaluation of NOS expression by Western blotting. After euthana-
sia, ileal fragments from normal and mdx mice pretreated for 18 h
with vehicle or RLX, close to those used for functional studies, were
minced and homogenized in 500 l of cold lysis buffer [10 mmol/l
Tris HCl, pH 7.4, 10 mmol/l NaCl, 1.5 mmol/l MgCl2, 2 mmol/l
disodium EDTA, 1 mmol/l phenylmethylsulfonyl fluoride (PMSF),
1% Triton X-100, 20 g/ml leupeptin, 1 g/ml pepstatin, 1 mg/ml
Pefabloc, and 2.5 g/ml aprotinin]. Upon centrifugation at 13,000 g
for 10 min at 4°C, the supernatants were collected and the total protein
content was measured spectrophotometrically using micro-BCA Pro-
tein Assay Kit (Pierce). Samples of the supernatants, each containing
80 g of proteins, were electrophoresed by SDS-PAGE (200 V, 1 h)
using a denaturating 7.6% polyacrylamide gel and blotted onto nitro-
cellulose membranes (Amersham, Cologno Monzese, Italy; 150 V,
1 h). The membranes were blocked with PBS containing 0.1% Tween
(T-PBS) and 5% bovine serum albumin (BSA; Sigma) at room
temperature for 1 h and incubated overnight at 4°C with rabbit
polyclonal antisera to revealed the different NOS isoforms (NOS III,
1:50,000, Alexis, San Diego, CA; NOS II, 1:10,000, Calbiochem;
NOS I, 1:5,000, Chemicon). After washing with T-PBS, the mem-
branes were incubated with peroxidase-labeled goat anti-rabbit anti-
bodies (1:10,000; Vector, Burlingame, CA) for 1 h at room temper-
ature. Immunoreactivity was detected by the ECL chemiluminescence
assay (Amersham). Membranes were also immunostained with rabbit
polyclonal anti--actin antibodies (1:20,000, Sigma), assuming -
actin as control invariant protein. For each NOS isoform, quantita-
tive evaluation was performed by computer-assisted densitometry,
with each band corresponding to an individual mouse, using the
Scion Image Beta 4.0.2 image analysis program (Scion, Frede-
rick, MD).
Calculations and statistical analysis. The quantitative data are
given as the means  SE of the values of each experimental group.
For functional assays, the values of the treated preparations were
expressed either as percentage changes of the basal (control) values or
as grams. The number of ileal preparations used is indicated by n in
the results.
Statistical analysis was performed by Student’s t-test to compare
two experimental groups or one-way ANOVA followed by Newman-
Keuls multiple comparison post-test when more than two groups were
compared. P  0.05 was considered significant.
RESULTS
Ileal contractility in preparations from untreated mice. At
basal tension, all ileal preparations from both normal and
dystrophic mdx mice showed spontaneous phasic contractions
(Fig. 1), very irregular in frequency, which were not affected
by the muscarinic receptor antagonist atropine (1 mol/l) (n 6,
P 0.05) or by the nerve blocker TTX (1 mol/l) (n 6, P
0.05), indicating that they were not cholinergic and not nerve
mediated. The amplitude of the ileal spontaneous contractions
was abnormally higher in preparations from mdx mice in
respect to the normal ones (mean amplitude 0.38  0.07 g and
1.13  0.09 g, in normal and mdx mice, respectively; P 
0.05) (Figs. 1 and 2). Addition of the NO donor SNP (30
mol/l) to the bath medium caused a quick relaxation and
transiently reduced the amplitude of spontaneous contractions in
preparations from both normal (n  4) and mdx (n  4) mice
(Fig. 1).
In preparations from normal mice (n  16) addition of 50
nmol/l RLX, alone (n  8) or in combination with 1 mmol/l
L-Arg (n  8) to the bath medium did not significantly
influence the amplitude of the spontaneous contractions (P 
0.05). In a few cases (n  2) RLX, starting 30–40 min after
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addition to the bath medium, caused a slight decay of the basal
tension (up to 15%).
In preparations from mdx mice (n 16), RLX alone (n 4)
was able to reduce the amplitude of the spontaneous contrac-
tions up to 65% (P  0.05), thus making the motility pattern
similar to that observed in the normal mice. However, in most
cases (n  12) the above-described effects of RLX were only
observed when the hormone was added in combination with 1
mmol/l L-Arg (Figs. 1 and 3). This effect persisted up to 1 h
after the addition of the hormone to the bath medium (longer
times not observed). L-Arg alone (n  4) did not significantly
influence the amplitude of ileal spontaneous contractions
(P  0.05).
In preparations from both normal (n  6) and mdx (n  6)
mice, addition to the bath medium of the NO synthesis inhib-
itor L-NNA (1 mmol/l) or the guanylate cyclase inhibitor ODQ
(1 mol/l) did not significantly change the amplitude of the
spontaneous contractions (P  0.05). On the other hand, in the
mdx mice, either L-NNA (1 mmol/l) (n  6) or ODQ
(1 mol/l) caused an almost complete reversal of the effects of
RLX or RLX plus L-Arg (n 6) (P 0.05) (Figs. 1, 3, and 4).
In fact, both inhibitors greatly increased the amplitude of the
spontaneous contractions, thus restoring the initial, abnormal
motility pattern (Figs. 1 and 4). In preparations from mdx mice
(n  4), the previous addition of L-NNA or ODQ to the bath
medium completely prevented the effect of RLX or RLX plus
L-Arg (P  0.05).
Ileal contractility in preparations from vehicle- and RLX-
pretreated mice. At basal tension, the spontaneous motility of
ileal preparations from vehicle-pretreated (n  6) and RLX-
pretreated (n  6) normal mice was not different in amplitude
when compared with the normal untreated animals (P  0.05).
Preparations from mdx mice pretreated with the vehicle alone
(n  6) showed ileal spontaneous contractions similar to those
observed in the untreated mdx mice (Fig. 2). Conversely, the
ileal preparations from RLX-pretreated mdx mice (n  10)
showed a spontaneous motility whose amplitude was greatly
reduced (up to 70%) in respect to that observed in the untreated
Fig. 2. Comparison among the mean amplitudes of ileal spontaneous muscular
contractions in preparations from untreated normal, untreated mdx, and vehi-
cle- and RLX-pretreated mdx mice. The mean amplitude of spontaneous
contractions in the untreated mdx mice is threefold that of the normal ones.
Pretreatment of mdx mice with vehicle does not influence the mean amplitude
of the contractions, which instead is markedly depressed in the RLX-pretreated
mdx mice, reaching values obtained in normal animals. All values are means
SE of 6 preparations. *P  0.05 vs. both the normal and the mdx RLX-
pretreated; n.s., not significant vs. the normal (one-way ANOVA and New-
man-Keuls post-test)
Fig. 3. Effects of RLX plus L-Arg, L-NNA, and the guanylate cyclase inhibitor
1H-[1,2,4]oxadiazolo[4,3-a]-quinoxalin-1-one (ODQ) on the mean amplitude
of ileal spontaneous muscular contractions from mdx mice. Addition of RLX
(50 nmol/l) plus L-Arg (1 mmol/l) to the bath medium causes a marked
reduction of the mean amplitude of muscular contractions in the ileum of the
mdx mice, which become similar to the normal mice (see Fig. 2). Subsequent
addition of L-NNA (1 mmol/l) or ODQ (1 mol/l) to the bath medium reverses
the effects of RLX plus L-Arg. All values are means  SE of 6 preparations.
*P  0.05 vs. mdx, L-NNA, and ODQ; n.s., not significant vs. mdx (one-way
ANOVA and Newman-Keuls post-test).
Fig. 1. Spontaneous contractions in ileal preparations from normal and dys-
trophic (mdx) untreated mice. Top: representative traces showing spontaneous
contractions in normal (left) and mdx (right) mice. Note the greater amplitude
of the spontaneous contractions in preparations from mdx mice compared with
the normal ones. Middle: the NO donor sodium nitroprusside (SNP, 30 mol/l)
causes a quick relaxation and transiently reduces the amplitude of spontaneous
contractions in preparations from both normal (left) and mdx (right) mice. The
amplitude of the spontaneous contractions and the basal tension of both
preparations gradually recover within 5–6 min from the addition of SNP to the
bath medium. Relaxin (RLX): in the mdx mice, compared with the typical
trace (left), addition of 50 nmol/l RLX plus 1 mmol/l L-Arg (middle) causes a
reduction in amplitude of the spontaneous contractions, which become similar
to those obtained in preparations from normal mice. The nitric oxide synthase
(NOS) inhibitor NG-nitro-L-arginine (L-NNA) (1 mmol/l), added to the bath
medium 20 min after RLX and L-Arg (right), reverses the effects of RLX and
L-Arg.
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and the vehicle-pretreated mdx mice (P  0.05) (Figs. 2 and 5).
Addition of RLX (50 nmol/l) plus L-Arg (1 mmol/l) to the bath
medium (n  4) did not further reduce the amplitude of the
spontaneous contractions (P  0.05) (Fig. 5). Addition of
L-NNA (1 mmol/l) to the bath medium caused an increase in
amplitude of the spontaneous contractions (P  0.05) (Fig. 5).
Ileal expression of NOS isoforms in vehicle- and RLX-
pretreated mice. Immunohistochemistry of the different NOS
isoforms in the normal vehicle-pretreated mice showed a dif-
ferent distribution pattern: NOS I was expressed by some
intrinsic neurons of the myenteric and submucous plexuses,
while NOS II and NOS III were observed in neurons and in
smooth muscle cells of the circular and longitudinal layers. By
visual examination, the ileum of the vehicle-pretreated mdx
mice showed a reduction of the intensity of NOS II immuno-
reactivity in the smooth muscle layers compared with their
normal counterparts. Pretreatment with RLX caused a clear-cut
increase in muscle NOS II immunoreactivity in the mdx mice
(Fig. 6). On the other hand, NOS II immunoreactivity in the
neurons was similar either in the vehicle- and RLX-pretreated
mdx mice (Fig. 6A). The immunoreactivities for NOS I and
NOS III were not visually different in the vehicle- and RLX-
pretreated normal and mdx mice (data not shown). No histo-
logical or histopathological differences were observed between
ileal fragments from normal and mdx mice.
By Western blotting, the ileal expression of NOS II was
lower in the mdx than in the normal vehicle-pretreated mice.
RLX pretreatment caused a clear-cut increase in the ileal
expression of NOS II in the mdx mice (Fig. 7). In keeping with
the immunofluorescence data, no appreciable differences in the
expression of NOS I were observed between RLX- and vehi-
cle-pretreated normal and mdx animals. A slight, not statisti-
cally significant increase in NOS III expression was found in
the RLX-pretreated normal and mdx mice (optical density:
70  9 and 100.1  12.6, respectively) compared with their
vehicle-treated counterparts (optical density: 65.7  8.2 and
78.1  15.6, respectively; P  0.05).
RLX plasma levels in vehicle- and RLX-pretreated mice. The
RLX plasma levels measured at death, i.e., 18 h after a single
subcutaneous injection of 2 g RLX in benzopurpurin vehicle,
were 43.4  2.5 pg/ml in the normal mice and 35  3.1 pg/ml
in the mdx mice. On the other hand, in mice treated with
vehicle alone, endogenous RLX was always below sensitivity
threshold of the used assay.
DISCUSSION
The occurrence of myogenic spontaneous motility has been
widely reported in both circular and longitudinal ileal muscles
of several animal species and in humans (9, 11, 24, 44, 47, 53).
In the present experiments, abnormally elevated spontaneous
contractions were observed in ileal muscle preparations from
mdx mice compared with the control ones.
Gastrointestinal motor disorders have been reported in the
mdx mice and related to a defective production/release of NO
(1, 7, 33). NO, released from enteric nerves, is considered the
major inhibitory neurotransmitter involved in gastrointestinal
relaxation, and its inhibitory role on neurally induced contrac-
tions have been clearly demonstrated (14, 30, 39, 52). How-
ever, in the present experiments, the intestinal spontaneous
contractions were not influenced by TTX, thus confirming their
myogenic nature (9, 11, 47). Furthermore, the lack of effects of
L-NNA or ODQ on the ileal spontaneous contractions of either
Fig. 4. Reversal by ODQ of the effects of RLX plus L-Arg on ileal sponta-
neous muscular contractions from mdx mice. Compared with the typical trace
(left), addition of 50 nmol/l RLX plus 1 mmol/l L-Arg (middle) causes a
reduction in amplitude of the spontaneous contractions. The guanylate cyclase
inhibitor ODQ (1 mol/l, right), added to the bath medium 20 min after RLX
and L-Arg, reverses the effects of RLX and L-Arg.
Fig. 5. Spontaneous contractions in ileal preparations from RLX-pretreated
mdx mice. Top: typical traces showing spontaneous contractions in ileal
preparations from vehicle-pretreated (left) and RLX-pretreated (right) mdx
mice. Note the lower amplitude of the spontaneous contractions in the
RLX-pretreated mdx mice compared with the vehicle-pretreated ones. Bottom:
compared with the RLX-pretreated mdx mice (left), addition of 50 nmol/l RLX
plus 1 mmol/l L-Arg (middle) does not further influence the amplitude of the
spontaneous contractions. The NO synthesis inhibitor L-NNA (1 mmol/l),
added to the bath medium 20 min after RLX and L-Arg (right), markedly
increases the amplitude of the spontaneous contractions.
Fig. 6. Representative pictures of NOS II immunoreactivity in the ileum of
vehicle- and RLX-pretreated normal and mdx mice (scale bars 25 m). A: in
vehicle-pretreated normal animals the labeling is detected in the muscle coat
and in the intrinsic neurons (arrows). B: in RLX-pretreated normal mice the
labeling appears substantially similar to the vehicle-pretreated ones. C: in
vehicle-pretreated mdx mice there is a clear-cut reduction of the labeling
intensity in the muscle coat. D: in RLX-pretreated mdx mice the labeling is
more intense than in the vehicle-pretreated counterparts and overlaps that of
normal mice. No apparent changes in NOS II immunoreactivity there were in
the neurons of all groups of animals.
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normal or mdx mice makes unlikely that an impaired NO
release from nervous elements may be involved in the abnor-
mally elevated motility. The ineffectiveness of NO synthesis
inhibitors and ODQ on intestinal spontaneous contractions has
been also observed in other animal species and in humans (9,
25, 47, 53).
Evidence is accumulating that NO produced by smooth
muscle cells (23) or other cell types (35, 38, 51) can greatly
influence the motor responses of the gastrointestinal smooth
muscle. Increased NO production, caused by NOS II (iNOS)
overexpression, has been reported to cause gut motor dysfunc-
tions and to greatly reduce intestinal smooth muscle contrac-
tility (25, 29, 50). Conversely, impaired myogenic NO produc-
tion has been reported to occur in the gut of mdx mice in which
an enhanced tone and irregular colonic peristaltic activity have
been described (33). The irregular peristaltic activity observed
in the colon of young mdx mice appears related to the absence
of NOS II expression (49).
In the present study, the reduction of NOS II expression in
ileal muscle cells of mdx mice supports that a defective
myogenic NO production may be involved in the abnormal
spontaneous contractions. The depression by SNP of the spon-
taneous contractions, either in normal or mdx mice, confirms
the major influence of NO on intestinal motility.
Evidence exists that the peptide hormone RLX potentiates
the NO signaling pathway in cells, tissues, and organs of
several animal species by upregulating NOS expression and
endogenous NO biosynthesis (4, 8, 9, 18, 20, 40, 42). In the
current study, addition of RLX to the bath medium greatly
reduced the amplitude of the abnormally elevated spontaneous
contractions observed in the ileum of dystrophic mdx mice.
Furthermore, ileal samples from RLX-pretreated mdx mice
showed a clear-cut increase in NOS II expression associated
with a motility pattern similar to the normal mice. The involve-
ment of NO in the inhibition of ileal spontaneous contractions
caused by RLX is further supported by the observation that
L-NNA could reverse the effects of the hormone itself and that,
in some acute experiments on untreated mdx mice, the pres-
ence of L-Arg into the bath medium was required to fully
obtain the depression of the spontaneous contractions by RLX.
These findings suggest that, in the mdx mice, not only is NOS
II expression reduced, as indicated by the immunohistochem-
ical and Western blot analysis, but a defect in L-Arg bioavail-
ability also occurs, consistently with the so-called “arginine
paradox” (32, 36). Therefore, the presence of a normal spon-
taneous motility in ileal preparations from RLX-pretreated
mdx mice suggests that this hormone potentiates NO biosyn-
thesis by increasing NOS II expression and/or by enhancing
L-Arg bioavailability. In our study, we also found a slight
increase in NOS III expression in the RLX-pretreated normal
and mdx mice compared with their vehicle-pretreated counter-
parts. This finding is in keeping with previous reports that RLX
administration causes an upregulation of NOS III in different
cells and tissues (reviewed in Refs. 20 and 40). Conceivably, in
the mdx mice, the increased NOS III could also generate NO,
but its contribution to the observed restoration of the ileal
motility pattern is likely negligible compared with NOS II.
The lack of effects of RLX addition to the bath medium on
ileal preparations from RLX-pretreated mdx mice, once the
spontaneous motility has been restored, may also account for
the ineffectiveness of the hormone to influence the amplitude
of ileal contractions in the normal mice. The discrepancy with
the results of our previous studies in the normal female mice,
in which RLX did depress ileal spontaneous motility (9), is
likely ascribable to sex-related differences in L-Arg plasma
levels and metabolism as well as in NO production, which may
be influenced by sex hormones (2, 21, 28, 41). Nevertheless, in
the mdx mice, the effects of RLX are manifest despite male
sex, so indicating that when a defective myogenic NO mech-
anism controlling spontaneous motility occurs, the hormone is
able to compensate for the NO defect until a normal sponta-
neous motility has been restored.
In conclusion, the present results suggest that a defective NO
production occurs in the ileum of mdx mice and that RLX can
restore the spontaneous motility chiefly by upregulating NOS
II and endogenous NO biosynthesis at the smooth muscle level.
Thus, RLX could be included among the new potential thera-
peutic approaches in the treatment of the gastrointestinal dis-
turbances in DMD. In this view, it is worth noting that
insulin-like growth factor, which belongs to a cognate hormone
family to that of RLX, has been reported to enhance NO
production (34) and to relieve muscle dysfunction in mdx mice
(22), thus being proposed for future clinical trials (17).
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